Molecularly targeted therapy and immunotherapy for hormone receptor‑positive/human epidermal growth factor receptor 2‑negative advanced breast cancer (Review)-Reference-Cited by-同舟云学术

Molecularly targeted therapy and immunotherapy for hormone receptor‑positive/human epidermal growth factor receptor 2‑negative advanced breast cancer (Review)

Published:2020-04-21 Issue: Volume: Page:
ISSN:1021-335X
Container-title:Oncology Reports
language:
Short-container-title:Oncol Rep

Author:

Song Yuhua¹,He Lin¹,Wang Yaling²,Wu Qian¹,Huang Wenzhi³

Affiliation:

1. Breast Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China

2. Department of Oncology, The Second Affiliated Hospital of Medical College of Qingdao University, Qingdao, Shandong 266000, P.R. China

3. Department of Oncology, The PLA Navy Anqing Hospital, Anqing, Anhui 246000, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology,General Medicine

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined Immunotherapy and Targeted Therapies for Cancer Treatment: Recent Advances and Future Perspectives;Current Cancer Drug Targets;2023-04

2. PLGA-based drug delivery system for combined therapy of cancer: research progress;Materials Research Express;2021-12-01

3. Esomeprazole affects the proliferation, metastasis, apoptosis and chemosensitivity of gastric cancer cells by regulating lncRNA/circRNA-miRNA-mRNA ceRNA networks;ONCOL LETT;2020

4. PD‑L1/PD‑1 blockade in breast cancer: The immunotherapy era (Review);Oncology Reports;2020-11-03

5. Nanoliposomes as Multidrug Carrier of Gemcitabine/Paclitaxel for the Effective Treatment of Metastatic Breast Cancer Disease: A Comparison with Gemzar and Taxol;Advanced Therapeutics;2020-09-06